Canakinumab for the Prevention of Recurrences After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (CONVERT-AF) Trial - A Randomized Double Blind Placebo Controlled Study
Phase of Trial: Phase II
Latest Information Update: 18 Mar 2017
At a glance
- Drugs Canakinumab (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms CONVERT-AF
- 31 Aug 2018 Biomarkers information updated
- 31 Jan 2017 Status changed from recruiting to discontinued.
- 15 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.